이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Incannex Healthcare 관리

관리 기준 확인 2/4

Incannex Healthcare's CEO는 Joel Latham, Jun2018 에 임명되었습니다 의 임기는 5.5 년입니다. 총 연간 보상은 A$ 3.03M, 27% 로 구성됩니다. 27% 급여 및 73% 보너스(회사 주식 및 옵션 포함). 는 A$ 59.16K 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 59.16K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 4.3 년입니다.

주요 정보

Joel Latham

최고 경영자

AU$3.0m

총 보상

CEO 급여 비율	27.0%
CEO 임기	5.5yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Joel Latham 의 보수는 Incannex Healthcare 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2023	AU$3m	AU$820k	-AU$20m
Mar 31 2023	n/a	n/a	-AU$19m
Dec 31 2022	n/a	n/a	-AU$18m
Sep 30 2022	n/a	n/a	-AU$17m
Jun 30 2022	AU$2m	AU$534k	-AU$15m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	n/a	n/a	-AU$13m
Sep 30 2021	n/a	n/a	-AU$12m
Jun 30 2021	AU$636k	AU$279k	-AU$11m
Dec 31 2020	n/a	n/a	-AU$6m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$390k	AU$227k	-AU$4m
Dec 31 2019	n/a	n/a	-AU$2m
Sep 30 2019	n/a	n/a	-AU$2m
Jun 30 2019	AU$204k	AU$170k	-AU$1m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$162k	AU$121k	-AU$3m

보상 대 시장: Joel 의 총 보상 ($USD 2.00M )은 Australian 시장( $USD 298.77K ).

보상과 수익: 회사가 수익성이 없는 동안 Joel 의 보상이 증가했습니다.

CEO

Joel Latham (33 yo)

5.5yrs

테뉴어

AU$3,033,966

보상

Mr. Joel Bradley Latham has been Chief Executive Officer at Incannex Healthcare Limited (also known as Impression Healthcare Ltd.) since June 29, 2018, Managing Director and Executive Director since July 2...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joel Latham	MD, CEO & Executive Director	5.5yrs	AU$3.03m	0.060% A$ 59.2k
Madhukar Bhalla	CFO & Company Secretary	2.4yrs	AU$84.00k	데이터 없음
Lekhram Changoer	Chief Technical Officer	1.5yrs	AU$157.50k	데이터 없음
Mark Bleackley	Chief Scientific Officer	no data	데이터 없음	데이터 없음
John Michailidis	Chief Executive Officer of IncannexTM	4.1yrs	데이터 없음	데이터 없음
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	데이터 없음	데이터 없음
Joseph Swan	Head of Finance	1.3yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: IHL 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joel Latham	MD, CEO & Executive Director	4.4yrs	AU$3.03m	0.060% A$ 59.2k
Mark Bleackley	Chief Scientific Officer	no data	데이터 없음	데이터 없음
Rosemarie Walsh	VP of Clinical Operations & Member of the Advisory Board	no data	데이터 없음	데이터 없음
Terrance O'Brien	Member of the Advisory Board	no data	데이터 없음	데이터 없음
George Anastassov	Non-Executive Director	1.5yrs	AU$175.87k	0.17% A$ 166.8k
Troy Valentine	Independent Non-Executive Chairman	6yrs	AU$1.38m	0.031% A$ 30.8k
Peter Widdows	Independent Non-Executive Director	5.8yrs	AU$316.23k	0.043% A$ 42.6k
Rondhir Jithoo	Member of Medical Advisory Board	4.3yrs	데이터 없음	데이터 없음
Paul Liknaitzky	Member of Medical Advisory Board	3.3yrs	데이터 없음	데이터 없음
Jennifer Walsh	Member of the Advisory Board	no data	데이터 없음	데이터 없음
Robert Clark	Non-Executive Director	1.3yrs	AU$176.09k	0% A$ 0

4.3yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 이사회: IHL 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Incannex Healthcare 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Recent updates

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

New minor risk - Share price stability

New minor risk - Financial data availability

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

New minor risk - Market cap size

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Less than half of directors are independent

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.012 loss in FY 2021)

Less than half of directors are independent

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Less than half of directors are independent

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Incannex Healthcare Limited Completes Dosing Patients in Phase 2 Proof-Of-Concept Trial of IHL-42X for the Treatment of Obstructive Sleep Apnoea

First half 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in 1H 2020)

Incannex Healthcare Limited Files International Patent Application Entitled "Methods for the Treatment of Obstructive Sleep Apnoea" as Part of the IHL-42X Development Program

Company Secretary Glenn Fowles has left the company

Incannex Healthcare Limited Initiates Sixth Research Program Following More Positive in Vivo Results

Incannex Healthcare Limited Partners with Monash Trauma Group At the Department of Neuroscience to Conduct Study in Relation to Neuroprotective Capability of IHL-216A

Incannex Healthcare Limited Initiates Fifth Research Program Following Further Positive in Vivo Results

New 90-day high: AU$0.23

Incannex Healthcare Limited Receives Positive Results from Another in Vivo (Animal) Study

Incannex Healthcare Limited, Annual General Meeting, Jan 25, 2021

Incannex Healthcare Limited Announces Positive Results from IH-216A TBI/Concussion Study

Incannex Healthcare Limited Receives Positive Results from Eurofins

Incannex Healthcare Limited Receives Further Positive Results from Eurofins (Taiwan)

Incannex Healthcare Limited Receives Ethics Approval for Phase 2 OSA Trial

Incannex Healthcare Limited Appoints Paul Liknaitzky to Medical Advisory Board as Scientific Officer

Full year earnings released - AU$0.0058 loss per share

An unknown buyer acquired Gameday International Pty Ltd from Incannex Healthcare Limited (ASX:IHL) for $0.29 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령